Bristol Myers rose 2.7% in pre-market trading after closing Friday at $65.31, just shy of a 52-week high and its highest level since June 22, 2023. AstraZeneca holds a market capitalisation of approximately $264 billion, while Bristol Myers Squibb adds roughly $133 billion. AstraZeneca's NYSE-listed shares ended Friday's session at $169.64, down $1.70 on the day, and sit more than $40 below their 52-week high of $212.71. Bristol Myers Squibb, meanwhile, closed Friday at $65.31, a whisker from its own 52-week high of $65.66 printed intraday on above-average volume of 14.58 million shares. Bristol Myers Squibb, meanwhile, has pursued acquisitions to reinvigorate a pipeline under pressure from patent cliffs, with GAAP R&D spending falling roughly 11% to approximately $10 billion in 2025.